Teva hosting investor call today at 8:00 a.m. ET (U.S.)Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD),…
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis…
London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Mendus (OMX: IMMU)Mendus continues to make headway…
The report from The Insight Partners lists several stakeholders—including pharmaceutical and biotech companies, CROs, regulatory authorities, healthcare providers, and academic…
Agreement signed to establish collaboration between IAVI and IPDNew partnership aims to accelerate vaccine development and manufacturing for priority pathogens…
Evaxion’s AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patientsNovel preclinical…
New AARP CEO Dr. Myechia Minter-Jordan to Discuss Innovations Shaping the Future of Aging and Well-Being WASHINGTON, Dec. 11, 2024…
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6…
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…
HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing…